Who Paid My Doc
David Aboulafia
Hematology & Oncology Seattle, WA Medical Doctor
NPI 1043269392 CMS profile 1246762
1100 9Th Ave, Seattle, WA 98101
General payments
$22,455
Research payments
$30,255
Ownership & investment interest
$0
Research they led as principal investigator
$348,819
Through program year 2025, David Aboulafia of Seattle, WA is reported in the CMS Open Payments database as having received $22,455 across 29 general payments and $30,255 in research payments paid to them. Separately, studies naming them as principal investigator received $348,819 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 89th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,412 | 5 | |
| 2024 | General | $2,865 | 1 | |
| 2023 | General | $3,071 | 2 | |
| 2021 | General | $2,963 | 5 | |
| 2020 | General | $2,767 | 3 | |
| 2019 | General | $8,377 | 13 | |
| 2019 | Research | $30,255 | 2 |
Beside peers
- David Aboulafia
- Hematology & Oncology median
- Middle half of Hematology & Oncology
- National median
In program year 2025, general payments to David Aboulafia were reported at $2,412. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.
Show as a table
| Year | David Aboulafia | Hematology & Oncology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $8,377 | $529 | $121–$2,516 | $163 |
| 2020 | $2,767 | $339 | $82–$2,213 | $114 |
| 2021 | $2,963 | $263 | $49–$1,965 | $132 |
| 2022 | $0 | $416 | $103–$2,395 | $149 |
| 2023 | $3,071 | $542 | $125–$2,646 | $160 |
| 2024 | $2,865 | $692 | $141–$3,008 | $164 |
| 2025 | $2,412 | $683 | $143–$3,154 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 107 drugsPart D claims
4,066
Drug cost
$9,095,416
Branded share of claims
45.6%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Juluca Dolutegravir/Rilpivirine | Brand | 223 | $815,964 | |
| Pomalyst Pomalidomide | Brand | 37 | $798,125 | |
| Revlimid Lenalidomide | Brand | 44 | $745,498 | |
| Ojjaara Momelotinib Dihydrochloride | Brand | 26 | $722,103 | |
| Lenalidomide | Generic | 55 | $708,067 | |
| Odefsey Emtricitab/Rilpiviri/Tenof Ala | Brand | 150 | $619,331 | |
| Brukinsa Zanubrutinib | Brand | 40 | $586,485 | |
| Ninlaro Ixazomib Citrate | Brand | 36 | $460,850 | |
| Jakafi Ruxolitinib Phosphate | Brand | 24 | $424,610 | |
| Biktarvy Bictegrav/Emtricit/Tenofov Ala | Brand | 88 | $412,583 |
The 10 drugs with the highest cost, of 107 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 8,746 Part D prescribers listed as Hematology-Oncology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 27 billing codesPaid by Medicare
$126,725
Medicare patients
445
Services billed
3,145
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 61% | |
| Arthritis | 41% | |
| Ischemic heart disease | 26% | |
| Chronic kidney disease | 24% | |
| Cancer | 24% | |
| Diabetes | 23% | |
| Atrial fibrillation | 22% | |
| Depression | 19% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
31 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Hematology & Oncology in Washington
Related records
Hematology & Oncology in Washington
Practitioners in the same specialty and state, ranked by reported value.
All Hematology & Oncology
Everyone recorded under this specialty, nationwide.
Doctors in Washington
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.